JP2015505553A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015505553A5 JP2015505553A5 JP2014555212A JP2014555212A JP2015505553A5 JP 2015505553 A5 JP2015505553 A5 JP 2015505553A5 JP 2014555212 A JP2014555212 A JP 2014555212A JP 2014555212 A JP2014555212 A JP 2014555212A JP 2015505553 A5 JP2015505553 A5 JP 2015505553A5
- Authority
- JP
- Japan
- Prior art keywords
- particle size
- administration
- dosage form
- active compound
- pharmaceutical dosage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002245 particle Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000002159 nanocrystal Substances 0.000 description 2
- 238000000498 ball milling Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12000743 | 2012-02-03 | ||
| EP12000743.0 | 2012-02-03 | ||
| PCT/EP2013/051979 WO2013113857A1 (en) | 2012-02-03 | 2013-02-01 | (1r,4r)-6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro-[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine for treating fibromyalgia and chronic fatigue syndrome |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015505553A JP2015505553A (ja) | 2015-02-23 |
| JP2015505553A5 true JP2015505553A5 (https=) | 2016-03-31 |
| JP6126134B2 JP6126134B2 (ja) | 2017-05-10 |
Family
ID=47628188
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014555212A Active JP6126134B2 (ja) | 2012-02-03 | 2013-02-01 | 線維筋痛症および慢性疲労症候群の治療のための、（１ｒ，４ｒ）−６’−フルオロ−（Ｎ−メチル−またはＮ，Ｎ−ジメチル−）−４−フェニル−４’，９’−ジヒドロ−３’Ｈ−スピロ［シクロヘキサン−１，１’−ピラノ［３，４，ｂ］インドール］−４−アミン |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20130202701A1 (https=) |
| EP (1) | EP2809320B1 (https=) |
| JP (1) | JP6126134B2 (https=) |
| KR (1) | KR102061482B1 (https=) |
| CN (1) | CN104168897B (https=) |
| AU (1) | AU2013214223B2 (https=) |
| BR (1) | BR112014019136A8 (https=) |
| CA (1) | CA2863572C (https=) |
| CY (1) | CY1118799T1 (https=) |
| DK (1) | DK2809320T3 (https=) |
| EA (1) | EA025500B1 (https=) |
| ES (1) | ES2629211T3 (https=) |
| HR (1) | HRP20170581T1 (https=) |
| IL (1) | IL233871B (https=) |
| LT (1) | LT2809320T (https=) |
| MX (1) | MX353740B (https=) |
| NZ (1) | NZ629800A (https=) |
| PL (1) | PL2809320T3 (https=) |
| PT (1) | PT2809320T (https=) |
| RS (1) | RS56097B1 (https=) |
| SI (1) | SI2809320T1 (https=) |
| WO (1) | WO2013113857A1 (https=) |
| ZA (1) | ZA201406447B (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6673924B2 (ja) | 2015-01-23 | 2020-03-25 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 肝機能障害および／または腎機能障害を有する対象における疼痛を治療するためのセブラノパドール |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5900420A (en) * | 1997-06-19 | 1999-05-04 | Cole; William L. | Method for treating chronic fatigue syndrome and fibromyalgia with buprenorphine |
| DE10252667A1 (de) * | 2002-11-11 | 2004-05-27 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| DE10360792A1 (de) * | 2003-12-23 | 2005-07-28 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| US7354925B2 (en) * | 2004-03-29 | 2008-04-08 | Pfizer Inc. | Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as ORL1-receptor antagonists |
| AU2007254751A1 (en) * | 2006-05-31 | 2007-12-13 | Sepracor Inc. | Treatment of pain disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine and its formamide |
| DE102006046745A1 (de) * | 2006-09-29 | 2008-04-03 | Grünenthal GmbH | Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz |
-
2013
- 2013-02-01 EA EA201400857A patent/EA025500B1/ru not_active IP Right Cessation
- 2013-02-01 CA CA2863572A patent/CA2863572C/en not_active Expired - Fee Related
- 2013-02-01 SI SI201330672A patent/SI2809320T1/sl unknown
- 2013-02-01 WO PCT/EP2013/051979 patent/WO2013113857A1/en not_active Ceased
- 2013-02-01 PL PL13701807T patent/PL2809320T3/pl unknown
- 2013-02-01 DK DK13701807.3T patent/DK2809320T3/en active
- 2013-02-01 RS RS20170602A patent/RS56097B1/sr unknown
- 2013-02-01 LT LTEP13701807.3T patent/LT2809320T/lt unknown
- 2013-02-01 EP EP13701807.3A patent/EP2809320B1/en active Active
- 2013-02-01 NZ NZ629800A patent/NZ629800A/en not_active IP Right Cessation
- 2013-02-01 US US13/757,223 patent/US20130202701A1/en not_active Abandoned
- 2013-02-01 HR HRP20170581TT patent/HRP20170581T1/hr unknown
- 2013-02-01 ES ES13701807.3T patent/ES2629211T3/es active Active
- 2013-02-01 CN CN201380007809.0A patent/CN104168897B/zh not_active Expired - Fee Related
- 2013-02-01 KR KR1020147024696A patent/KR102061482B1/ko not_active Expired - Fee Related
- 2013-02-01 AU AU2013214223A patent/AU2013214223B2/en not_active Ceased
- 2013-02-01 BR BR112014019136A patent/BR112014019136A8/pt not_active Application Discontinuation
- 2013-02-01 JP JP2014555212A patent/JP6126134B2/ja active Active
- 2013-02-01 PT PT137018073T patent/PT2809320T/pt unknown
- 2013-02-01 MX MX2014008865A patent/MX353740B/es active IP Right Grant
-
2014
- 2014-07-30 IL IL233871A patent/IL233871B/en active IP Right Grant
- 2014-09-02 ZA ZA2014/06447A patent/ZA201406447B/en unknown
-
2017
- 2017-04-03 CY CY20171100395T patent/CY1118799T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009512663A5 (https=) | ||
| CY1124878T1 (el) | Διασπειρομενη στο στομα δοσολογικη μοναδα η οποια περιεχει ενα συστατικο οιστετρολης | |
| WO2013132457A3 (en) | Nanocrystalline solid dispersion compositions and process of preparation thereof | |
| HRP20250776T1 (hr) | Elafibranor za uporabu u liječenju primarnog bilijarnog kolangitisa | |
| JP2016065086A5 (https=) | ||
| JP2012255026A5 (https=) | ||
| HN2011000864A (es) | Particulas inhalables que comprenden tiotropio | |
| ECSP11011289A (es) | Formulaciones galénicas de compuestos orgánicos | |
| WO2012051426A3 (en) | Aggregate nanoparticulate medicament formulations, manufacture and use thereof | |
| UA112296C2 (uk) | Сухий порошковий препарат, який містить інгібітор фосфодіестерази | |
| JP2015526455A5 (https=) | ||
| JP2015510916A5 (https=) | ||
| JP2016513625A5 (https=) | ||
| CY1124635T1 (el) | Ξηρες φαρμακευτικες συνθεσεις που περιεχουν νανοσωματιδια ενεργου παραγοντα δεσμευμενα σε σωματιδια φορεα | |
| PH12014501545A1 (en) | Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof | |
| JP2015520241A5 (https=) | ||
| JP2016540000A5 (https=) | ||
| JP2014062109A5 (https=) | ||
| JP2015505553A5 (https=) | ||
| WO2014167579A3 (en) | Stable pharmaceutical compositions of tadalafil | |
| EA201591871A1 (ru) | Фармацевтическая композиция, содержащая будесонид и формотерол | |
| JP2011251959A5 (https=) | ||
| JP2016523943A5 (https=) | ||
| MX385513B (es) | Composiciones farmaceuticas que comprenden safinamida. | |
| JP2015536957A5 (https=) |